Aktis Oncology, Inc.

US$15.82As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:AKTSHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE —
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap US$879.9M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$20
29.14%
(30.63%)
Hold 2|3|3|10|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.28
0.27
0.26
0.28
14.98%
13.75%
1.37%
1.27%
Revenue$M
80.21
83.01
83.77
83.87
2.01%
4.85%
4.46%
3.17%
Peers (US$879.9M)
Cap (US$)
PE
864.4M
9.592x
875.4M
43.62x
Capital
TTM
5Y
10Y
Leveragex
0.347
—
—
EBIT/Intx
0.166
0.408
0.407
Own earn%
28.38
(76.10)
(77.59)
Sh yield%
24.17
25.80
27.86
Owners
Insiders/Inst%
3.38
59.48
Short interest%
5.72
SBC / revenue%
4.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
17–25
$1 testx
0.0
Incr. ROIC%
30